Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)
Japan
· Delayed Price · Currency is JPY 1,287.00
-8.00 (-0.62%)
May 20, 2025, 3:30 PM JST
TYO:2395 Revenue
In the fiscal year ending March 31, 2025, Shin Nippon Biomedical Laboratories had annual revenue of 32.41B JPY with 22.55% growth. Shin Nippon Biomedical Laboratories had revenue of 10.18B in the quarter ending March 31, 2025, with 20.23% growth.
Revenue
32.41B
Revenue Growth
+22.55%
P/S Ratio
1.65
Revenue / Employee
22.57M
Employees
1,341
Market Cap
53.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 32.41B | 5.96B | 22.55% |
| Mar 31, 2024 | 26.45B | 1.36B | 5.42% |
| Mar 31, 2023 | 25.09B | 7.34B | 41.37% |
| Mar 31, 2022 | 17.75B | 2.64B | 17.46% |
| Mar 31, 2021 | 15.11B | 549.00M | 3.77% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,581.55B |
| HOYA Corporation | 869.37B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 997.33B |